Latest advances in cannabinoid receptor antagonists and inverse agonists

被引：37
作者：
Muccioli, Giulio G.
Lambert, Didier M.
机构：
[1] Univ Catholique Louvain, Drug Design & Discovery Ctr, B-1200 Brussels, Belgium
[2] Univ Catholique Louvain, Unite Chim Pharmaceut & Radiopharm, B-1200 Brussels, Belgium
[3] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2006年 / 16卷 / 10期
关键词：
cannabinoid; CB1; antagonists; CB1 inverse agonist; CB2; inverse agonists; JTE-907; SR141716; SR147778; SLV319; Sch225336;
D O I：
10.1517/13543776.16.10.1405
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
This review covers the progress made in the field of CB1 and CB2 cannabinoid receptor antagonists and inverse agonists since 2004. The high therapeutic potential of these compounds is reflected by the great number of patents filed during the last 3 years. Although the vast majority of the patents are related to CB1 due to the known therapeutic potential of CB1 antagonists, several compounds acting at CB2 have also been disclosed. Obesity, metabolic syndrome and smoking cessation are CB1 antagonists indications supported by the recent clinical trials results.
引用
收藏
页码：1405 / 1423
页数：19
相关论文
共 172 条
[71]  
Kruse C. G., 2003, [No title captured], Patent No. [WO 2003027076 A2, 2003027076]
[72]  
LAB ESTEVE, 2005, Patent No. 2005077897
[73]  
LAGU B, 2005, Patent No. 2005095353
[74]   The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications [J].
Lambert, DM ;
Fowler, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (16) :5059-5087
[75]   Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity [J].
Lange, JHM ;
van Stuivenberg, HH ;
Veerman, W ;
Wals, HC ;
Stork, B ;
Coolen, HKAC ;
McCreary, AC ;
Adolfs, TJP ;
Kruse, CG .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4794-4798
[76]   Bioisosteric replacements of the pyrazole moiety of rimonabant:: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists [J].
Lange, JHM ;
van Stuivenberg, HH ;
Coolen, HKAC ;
Adolfs, TJP ;
McCreary, AC ;
Keizer, HG ;
Wals, HC ;
Veerman, W ;
Borst, AJM ;
de Looff, W ;
Verveer, PC ;
Kruse, CG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1823-1838
[77]   Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists [J].
Lange, JHM ;
Kruse, CG .
DRUG DISCOVERY TODAY, 2005, 10 (10) :693-702
[78]  
Lange JHM, 2004, CURR OPIN DRUG DISC, V7, P498
[79]   Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists [J].
Lange, JHM ;
Coolen, HKAC ;
van Stuivenberg, HH ;
Dijksman, JAR ;
Herremans, AHJ ;
Ronken, E ;
Keizer, HG ;
Tipker, K ;
McCreary, AC ;
Veerman, W ;
Wals, HC ;
Stork, B ;
Verveer, PC ;
den Hartog, AP ;
de Jong, NMJ ;
Adolfs, TJP ;
Hoogendoorn, J ;
Kruse, CG .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (03) :627-643
[80]  
LANGE JHM, 2005, Patent No. 2005040130
3456789101112